A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017)

Carlotta Granchi, Isabella Caligiuri, Filippo Minutolo, Flavio Rizzolio, Tiziano Tuccinardi

Research output: Contribution to journalReview articlepeer-review


Introduction: Monoacylglycerol lipase is a serine hydrolase that plays a major role in the degradation of the endocannabinoid 2-arachidonoylglycerol. Because of this key role, selective inactivation of MAGL represents an interesting approach to obtain desirable effects in several diseases. Furthermore, MAGL is upregulated in cancer cells and primary tumors and its inhibition in aggressive breast, ovarian, and melanoma cancer cells impairs cell migration, invasiveness, and tumorigenicity. Areas covered: This review covers patent literature on MAGL inhibitors and their applications published from 2013 to 2017. Expert opinion: MAGL inhibition has gained considerable importance in many therapeutic fields and one compound has been subjected to Phase I studies. Even if a reasonable number of patents have been recently reported, novel MAGL inhibitors are still required, especially novel chemical classes displaying a reversible mechanism of action.

Original languageEnglish
Pages (from-to)1341-1351
Number of pages11
JournalExpert Opinion on Therapeutic Patents
Issue number12
Publication statusPublished - Dec 2 2017


  • cancer
  • cannabinoids
  • inhibitors
  • MAGL
  • neurodegenerative disorders
  • Antineoplastic Agents

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017)'. Together they form a unique fingerprint.

Cite this